---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Limitations of current therapies"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Limitations of current therapies. Topics: Summary: limitations of cystectomy and of approved bladder-sparing therapies; Guideline position on radical cystectomy and bladder-sparing therapy; Cystectomy refusal, ineligibility, and perioperative risk; Limitations of approved bladder-sparing therapies stated by trial investigators; 4 further topics. 8 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Limitations of current therapies

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

### Summary: limitations of cystectomy and of approved bladder-sparing therapies

The EAU guideline states that radical cystectomy is the standard and preferred option for BCG-unresponsive disease and that other treatments must be considered oncologically inferior; it recommends bladder-preserving strategies, preferably within clinical trials, for patients who are not candidates for cystectomy or who decline it. Up to 80% of patients decline or are ineligible for cystectomy. Reported risks of the procedure include morbidity of 50% to 70% and 90-day mortality of approximately 5% (up to 15% in elderly patients), and a manufacturer-funded cost model states that up to one-quarter of patients die and approximately 70% to 80% experience complications within the first year after surgery.

Pembrolizumab, nogapendekin alfa inbakicept-pmln with BCG, and the gemcitabine intravesical system were each approved on the basis of single-arm trials. Their labeled complete response rates were 41% (96 participants), 62% (77 participants), and 82% (83 participants), and no randomized trial compares these agents with each other or with cystectomy. FDA draft guidance states that a randomized controlled trial is preferable and can provide stronger evidence of effectiveness, that time-to-event endpoints are uninterpretable in a single-arm trial, and that a single-arm study cannot assess the contribution of each drug in a combination. For papillary-only disease resected at or before trial entry, the FDA recommends a randomized controlled trial with a time-to-event endpoint. In October 2026, the FDA extended the nogapendekin alfa inbakicept-pmln indication to papillary-only disease by extrapolation from efficacy in disease containing CIS. Labeling for pembrolizumab and the gemcitabine intravesical system is limited to disease with CIS, and pembrolizumab is further limited to patients ineligible for or electing not to undergo cystectomy. Of 31 BCG-unresponsive trials registered on ClinicalTrials.gov, 15 (48%) had enrollment criteria fully consistent with the FDA definition, which the authors state hinders comparisons across agents.

In a meta-analysis of bladder-sparing trials after BCG failure cited by the EAU guideline, pooled 12-month response rates were 24% for trials with more than 2 prior BCG courses and 36% for those with more than 1, and initial response did not predict durable response. Among responders, 46% (pembrolizumab), 58% (nogapendekin alfa inbakicept-pmln with BCG), and 51% (gemcitabine intravesical system) had a duration of response of at least 12 months in the labels. In QUILT-3.032 Cohort A, complete response rates at the 12-, 24-, and 36-month assessments were 47%, 30%, and 16% of 100 participants; in SunRISe-1 Cohort 2, the complete response rate 12 months after treatment initiation was 45.9%. The QUILT-3.032 median duration of response was considered an unreliable estimate because of the limited sample size, small number of events, and substantial censoring. Progression to muscle-invasive disease occurred in 10% (8 participants) in QUILT-3.032 and 8% (7 of 83 evaluable participants) in SunRISe-1 Cohort 2, and each label warns that delaying cystectomy can lead to muscle-invasive or metastatic disease.

Nogapendekin alfa inbakicept-pmln is given with BCG, and TICE BCG is the only approved BCG strain marketed in the U.S. Merck, its sole U.S. manufacturer since 2012, allocates supply to wholesalers and distributors by historical purchasing patterns; in its 2026 letter to health care professionals it reported delays to full startup of a new facility and stated that it will provide an update on timing in the first quarter of 2027. In Medicare claims, BCG use for initial induction therapy decreased from 38.9% before the shortage to 33.0% during it.

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf); [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599); [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/); [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037); [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf); [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf); [FDA nogapendekin alfa inbakicept-pmln expanded indication notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle); [Chandra et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37061453/); [Chang et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13657391/); [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/); [Merck TICE BCG HCP letter (2026)](https://www.auanet.org/documents/about/Annual%20HCP%20Letter%20TICE%20BCG%20September%202026%20%28AUA%29.pdf); [Chun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11221414/)

<a id="topic-2.2.2.1.7-2"></a>

### Guideline position on radical cystectomy and bladder-sparing therapy

> “Patients with BCG-unresponsive disease are unlikely to respond to further BCG therapy; RC is therefore the standard and preferred option.”
> “Treatments other than RC must be considered oncologically inferior in patients with BCG-unresponsive tumours.”
> “Offer patients with BCG-unresponsive tumours, who are not candidates for RC due to comorbidities, or who decline RC, preservation strategies (intravesical chemotherapy, chemotherapy and microwave-induced hyperthermia, electromotive administration of chemotherapy, intravesical- or systemic immunotherapy; preferably within clinical trials).”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.7-3"></a>

### Cystectomy refusal, ineligibility, and perioperative risk

> “Treatment options for BCG-unresponsive patients with NMIBC are currently limited.”
> “up to 80% of patients decline or are ineligible for the procedure due to associated morbidity, mortality, or quality of life concerns”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

> “The current standard of care for BCG-unresponsive high-risk NMIBC is radical cystectomy,”
> “which is a life-changing surgery associated with considerable morbidity (50%-70%) and significant impact on quality of life.”
> “Radical cystectomy is also associated with substantial 90-day mortality risk (approximately 5%), particularly in elderly patients (≤15%).”
> “Therefore, many patients are unable or unwilling to undergo this procedure, and real-world rates of radical cystectomy for NMIBC are low (<20%).”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

> “In patients with BCG-unresponsive NMIBC with CIS, radical cystectomy (RC) is the standard of care”
> “However, up to one-quarter of patients die and approximately 70%-80% experience complications within the first year following surgery”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-2.2.2.1.7-4"></a>

### Limitations of approved bladder-sparing therapies stated by trial investigators

> “However, these treatments are associated with limited complete response (CR) rates and response durability, systemic or immune-related toxicities, frequent urethral catheterizations, reliance on BCG as combination therapy, and limited physician adoption.”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

> “However, outcomes with these treatments continue to be suboptimal, with the respective clinical trial data reporting overall CR rates of less than 55% and a 12-month duration of response (DOR) of less than 49%”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-2.2.2.1.7-5"></a>

### Single-arm trial evidence and FDA trial design recommendations

> “An RCT is preferrable and can”
> “provide stronger evidence of effectiveness, allow for evaluation of both CIS and”
> “papillary disease, and generate comparative safety data.”
> “Time-to-event endpoints are uninterpretable in a single-arm trial.”
> “When the investigational therapy consists of more than one drug, assessing the”
> “contribution of effect of each drug to the combination therapy is not possible in a”
> “single-arm study.”
> “For patients with papillary-only disease that was resected at or before trial entry, FDA”
> “recommends a randomized, controlled trial design using a time-to-event endpoint such as”
> “recurrence-free survival.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

> “However, the review of QUILT-3.032 highlighted several challenges in interpreting single-arm data in this disease setting.”
> “One key consideration is that both the primary endpoint of CRR and the key secondary endpoint of DoR may be impacted by heterogeneity across investigators in disease assessment.”
> “However, a randomized trial with a time-to-event endpoint would be required to demonstrate benefit in patients with papillary-only disease due to the lack of an available response endpoint for resected tumors and variability in the natural history of resected papillary disease, which challenges the interpretation of uncontrolled time-to-event endpoints.”

Source: [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

> “A limitation was the noncomparative cohort design.”
> “The duration of follow-up in the present analysis (median, 20.2 months in Cohort 2 responders) limits the ability to draw firm conclusions regarding long-term efficacy and safety of TAR-200 treatment”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-2.2.2.1.7-6"></a>

### Heterogeneity of trial enrollment criteria

> “Of 31 trials, 15 (48%) had inclusion/exclusion criteria that were fully consistent with (inclusive of patients that met) the BCG unresponsive bladder cancer definition.”
> “The most common disease specific exclusion for patients with BCG unresponsive bladder cancer was a requirement for stage Tis (carcinoma in situ, CIS), which pertained to 7 (23%) of trials.”
> “For bladder cancer treating physicians and regulatory bodies, this also hinders comparisons across agents.”

Source: [Chandra et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37061453/)

<a id="topic-2.2.2.1.7-7"></a>

### Durability of complete response

> “The significant heterogeneity of both trial designs and patient characteristics included in these studies, the different definitions of BCG failures used, and missing information on prior BCG courses may account for the variability in efficacy for the different compounds assessed across different trials.”
> “The pooled 12-month response rates were 24% for trials with > 2 prior BCG courses and 36% for those with > 1 BCG courses.”
> “Initial response rate did not predict durable responses highlighting the need for longer-term follow-up.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “At the 12-, 24-, and 36-month response assessments, CR rates were 47% (47 of 100; 95% CI 36.9%-57.2%), 30% (30 of 100; 95% CI 21.2%-40.0%), and 16% (16 of 100; 95% CI 9.4%-24.7%), respectively.”

Source: [Chang et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13657391/)

> “At 3, 6, and 12 months after treatment initiation, CR rates were 78.8% (95% CI, 68.6 to 86.9), 58.8% (95% CI, 47.6 to 69.4), and 45.9% (95% CI, 35.0 to 57.0), respectively.”
> “For context, among patients treated with pembrolizumab, nadofaragene firadenovec, or NAI plus BCG, 46%-58% had a DOR of ≥12 months, with CIs overlapping.”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

> “However, given the limited sample size, small number of events, and substantial censoring from approximately 12–15 months, the median DOR in QUILT-3.032 was considered an unreliable estimate.”
> “A post-marketing commitment to better characterize the response duration and risk for progression in all patients was agreed upon with the Applicant.”

Source: [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

<a id="topic-2.2.2.1.7-8"></a>

### BCG supply constraints

> “Since 2012, Merck has been the sole US manufacturer and primary global supplier of TICE BCG.”
> “Increasing global demand for TICE BCG has exceeded our manufacturing capabilities.”
> “While work is underway to address these issues, the cumulative additional time will delay full startup, filing, and approval of the facility.”
> “We will provide an update on the expected timing of our new facility’s opening in the first quarter of 2027.”
> “As a reminder, Merck continues to allocate available supply of TICE BCG to wholesalers and distributors, based on their historical purchasing patterns.”

Source: [Merck TICE BCG HCP letter (2026)](https://www.auanet.org/documents/about/Annual%20HCP%20Letter%20TICE%20BCG%20September%202026%20%28AUA%29.pdf)

> “Among eligible patients, BCG utilization rates for initial induction therapy decreased 5.9%, from 38.9% (1030 of 2648 patients) in the pre-shortage period, to 33.0% (1756 of 5323 patients) in the shortage period”

Source: [Chun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11221414/)

> “Ten (13%) patients in Cohort A received prior partial dose BCG, which was allowed due to the BCG supply issues during the conduct of the study.”

Source: [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

> “Furthermore, ongoing national BCG shortages since 2012 have constrained access to adequate BCG therapy, limiting treatment options for patients with NMIBC in the US and underscoring the need for additional effective therapies”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
